Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:41 AM
Ignite Modification Date:
2025-12-25 @ 2:41 AM
NCT ID:
NCT02674633
Eligibility Criteria:
Inclusion Criteria:
Confirmed ADHD diagnosis, any presentation, at Screening based on the Diagnostic and Statistical Manual of Mental Health-Fifth Edition criteria and established via the MINI-International Neuropsychiatric Interview for Children and Adolescents administered by a trained clinician
Screening/Baseline score on the clinician-rated ADHD-RS-IV score \>= 28
Screening/Baseline score on the TOVA 8 API \<= -1.8
Not undergoing pharmacological treatment with methylphenidate or amphetamine-based products at time of Screening; or, if undergoing pharmacological treatment, must be willing and appropriate (i.e. not optimally treated in the investigator's judgment) to wash out of current regimen
Ability to follow written and verbal instructions (English), as assessed by the PI
Estimated Intelligence Quotient score \>= 80 as assessed by the Kaufmann Brief Intelligence Test, Second Edition (KBIT-II)
Ability to comply with all the testing and requirements.
Exclusion Criteria:
Current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis, based on MINI-KID and subsequent clinical interviewing, with significant symptoms including but not limited to post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator that may confound study data/assessments. Participants with clinical history of learning disorders will be allowed to participate, provided the disorder does not impact their ability to participate in the trial based on PI judgment
Participants who are currently treated with a non-stimulant medication for ADHD (i.e., atomoxetine, clonidine clonidine, guanfacine)
Initiation within the last 4 weeks of behavioral therapy. Participants who have been in behavior therapy consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Participants planning on changing or initiating behavior therapy during the course of the study will be excluded
Participant is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation or self-injurious behavior as measured by Columbia Suicide Severity Rating Scale at screening
Motor condition (e.g., physical deformity of the hands/arms; prostheses) that prevents game playing as reported by the parent or observed by the investigator
Recent history (within the past 6 months) of suspected substance abuse or dependence
History of seizures (exclusive of febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder
Has participated in a clinical trial within 90 days prior to screening
Diagnosis of or parent-reported color blindness (Confirmed in-clinic via ICBT)
Uncorrected visual acuity (Confirmed in-clinic via ability of subject to play the intervention)
Regular use of psychoactive drugs (other than stimulant) that in the opinion of the Investigator may confound study data/assessments
Any other medical condition that in the opinion of the investigator may confound study data/assessments
Has a sibling also enrolled/currently participating in the same study
Has previously participated in a study of Akili's EVO videogame-like digital therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
8 Years
Maximum Age:
12 Years
Study:
NCT02674633
Study Brief:
Protocol Section:
NCT02674633